Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 1
1991 2
1993 2
1995 3
1996 3
1997 6
1998 9
1999 13
2000 17
2001 12
2002 14
2003 15
2004 8
2005 18
2006 10
2007 8
2008 11
2009 18
2010 27
2011 27
2012 29
2013 31
2014 19
2015 17
2016 17
2017 13
2018 17
2019 20
2020 25
2021 16
2022 17
2023 13
2024 10
2025 14
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Cong …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intran …
Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, Sedighiyan M, Diaz DN, Shafiei A. Ghanbari N, et al. Iran J Allergy Asthma Immunol. 2024 Jul 27;23(4):366-373. doi: 10.18502/ijaai.v23i4.16211. Iran J Allergy Asthma Immunol. 2024. PMID: 39549290 Free article. Clinical Trial.
Sixty-four children with persistent moderate to severe allergic rhinitis were enrolled and randomly divided into 4 groups. All children received mometasone furoate nasal spray once daily. In addition to mometasone, each group received one of the following dru …
Sixty-four children with persistent moderate to severe allergic rhinitis were enrolled and randomly divided into 4 groups. All children rece …
Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis: A Randomized Clinical Trial.
Latek M, Lacwik P, Molinska K, Blauz A, Lach J, Rychlik B, Strapagiel D, Majak J, Molinska J, Czech D, Seweryn M, Kuna P, Palczynski C, Majak P. Latek M, et al. JAMA Pediatr. 2023 Apr 1;177(4):345-352. doi: 10.1001/jamapediatrics.2022.6172. JAMA Pediatr. 2023. PMID: 36848113 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once per day) and supplemental 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (INC group) or 3-mL NaCl …
INTERVENTIONS: Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once …
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Wenzel S, et al. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27. Lancet. 2016. PMID: 27130691 Clinical Trial.
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. De Corso E, et al. Lancet Respir Med. 2025 Dec;13(12):1067-1077. doi: 10.1016/S2213-2600(25)00287-5. Epub 2025 Sep 28. Lancet Respir Med. 2025. PMID: 41033334 Clinical Trial.
Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosing every 2 weeks or 4 weeks for 24 weeks, with background mometasone furoate nasal spray. Patients and investigators were masked to th …
Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosing every …
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma. ...
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoa …
Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring: A Randomized Clinical Trial.
Ioerger P, Afshari A, Hentati F, Strober W, Kallogjeri D, Ju YE, Piccirillo JF. Ioerger P, et al. JAMA Otolaryngol Head Neck Surg. 2024 Jul 1;150(7):572-579. doi: 10.1001/jamaoto.2024.1035. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38780959 Free PMC article. Clinical Trial.
INTERVENTIONS: Fifty couples were randomized to either use a mandibular advancement device (MAD) or receive combined airway and positional therapy (CAPT; external nasal dilator, nasal saline lavage with mometasone, mouth taping, and lateral positional therapy). MAIN OUTCOM …
INTERVENTIONS: Fifty couples were randomized to either use a mandibular advancement device (MAD) or receive combined airway and positional t …
Safety and onset time of modified Yupingfeng nasal spray versus mometasone furoate nasal spray on house dust mites-induced moderate to severe allergic rhinitis: A prospective, multicenter, randomized, open-label, parallel-group clinical trial.
Wang H, Liu T, Liao C, Liang F, Tian L. Wang H, et al. J Ethnopharmacol. 2025 Mar 26;344:119574. doi: 10.1016/j.jep.2025.119574. Epub 2025 Mar 1. J Ethnopharmacol. 2025. PMID: 40032208 Clinical Trial.
AIM OF THE STUDY: Previous research has shown that both MYN and mometasone furoate nasal spray (MFN) can alleviate symptoms of HDM-induced AR. However, the safety and onset time of MYN compared to MFN for treating HDM-induced AR remain unclear. ...
AIM OF THE STUDY: Previous research has shown that both MYN and mometasone furoate nasal spray (MFN) can alleviate symptoms of …
Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis.
Lucendo AJ, Nantes-Castillejo Ó, Straumann A, Biedermann L, Bredenoord AJ, Guagnozzi D, Blas-Jhon L, Wiechowska-Kozlowska A, Weidlich S, von Arnim U, Santander-Vaquero C, Perelló A, Pérez-Martínez I, Barrio J, Vieth M, Gouya G, Dellon ES. Lucendo AJ, et al. Aliment Pharmacol Ther. 2025 Feb;61(3):444-455. doi: 10.1111/apt.18443. Epub 2024 Dec 16. Aliment Pharmacol Ther. 2025. PMID: 39676687 Free PMC article. Clinical Trial.
BACKGROUND: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE). ...Participants received placebo, uncoated EsoC …
BACKGROUND: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoat …
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT, Deans A, Mehta R, Sousa AR. Daley-Yates PT, et al. Pulm Pharmacol Ther. 2022 Dec;77:102171. doi: 10.1016/j.pupt.2022.102171. Epub 2022 Oct 13. Pulm Pharmacol Ther. 2022. PMID: 36243386 Clinical Trial.
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). METHODS: Study 1: Fourteen healthy participants received inhaled and i …
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate ( …
432 results